Urethral stricture is a medical condition, which causes narrowing of the urethra due to presence of a scar tissue, tissue inflammation, infection or injury. This condition can cause obstructive dysfunction of urethra with potentially serious consequences for the entire urinary tract. The urinary strictures are more common in males. They occur at any point along the urethra, but are most often seen in the bulbar region and can range from less than 1cm long to the entire length of the urethra. There are two types of urethral stricture conditions that occur in males, which include posterior and anterior urethral strictures.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2381

The cause of urethral stricture depends on the site of the stricture. Some of the common causes for this condition are idiopathic, inflammatory (caused by infection or chronic inflammation in urethra, e.g., lichen sclerosus), traumatic (caused due to injury to the urethra), iatrogenic (caused by medical intervention such as endoscopic procedures, urethral catheterization, radiotherapy or surgery to neighboring organs), and congenital (caused by inherited conditions such as hypospadias and epispadias).

Some of the common symptoms of urethral strictures includes painful urination, reduced urine output, incomplete emptying of the bladder, and inability to void. There are various types of treatment available for urethral strictures ranging from conservative or minimally invasive procedures to complex reconstructive procedures such as direct vision internal urethrotomy (DVIU), urethroplasty, urethral dilation, and others.

Urethral Stricture Treatment Market - Market Dynamics

Increasing cases of prostate cancers, injuries, and medical conditions requiring urethral stents, dilators, and catheters is one of the major factors for rise in urethral stricture cases, which in turn is driving growth of the urethral stricture treatment market.

According to the National Centers for Biotechnology & Information (NCBI), urethral stricture is a common disease with prevalence of over 400 per 100,000 population among males in year 2016 globally.  According to the Cancer Research UK, in males in the U.K., prostate cancer is the most common cancer with around 47,200 new cases registered in 2015. Moreover, the incidence rates of prostate cancer are projected to rise by 12% between 2014 and 2035, to 233 cases per 100,000 males by 2035 in the U.K., as per Cancer Research UK. High catheter associated urinary tract infection (CAUTI) rates of 6.8 per 1000 device days were observed in the UAE medical units in March 2015.

Moreover, advancements in development of therapies for treating urethral strictures is driving growth of the urethral stricture treatment market. For instance, a Germany-based company, MukoCell GmbH developed a tissue engineering-based product called MukoCell, which is used for repair of urethral strictures and hypospadias. This product is an alternative to conventional transplantation with native buccal mucosa.

However, high cost of surgical procedures and high rate of complications are some of the major factors restraining growth of the global urethral stricture treatment market. According to Healthcare Cost and Utilization Project (HCUP) 2016, the average cost of male urethroplasty can range between US$ 5,677–US$ 10,000 with an average increase of US$ 616 per year in the U.S.

Urethral Stricture Treatment Market – Regional Insights

On the basis of geography, the global urethral stricture treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America held dominant position in the global urethral stricture treatment market in 2017. This is owing to rising number of urethroplasties for urethral strictures in the region. Moreover, high adoption rate of innovative technologies and numerous product development is driving growth of the market. For instance, in February 2018, Urotronic, an early stage medical device company, received license for its product, Optilume drug-coated balloon (DCB), which will be used to treat urethral strictures in Canada. The development of this drug-coated ballon have a significant impact across Canada due to scarcity of physicians currently to perform majority of urethral stricture treatments.

Asia Pacific is expected to witness significant growth in the urethral stricture treatment market during the forecast period, owing to improving health care infrastructure in economies such as India and China, and increasing demand for efficient treatment options for urethral strictures.

Urethral Stricture Treatment Market – Competitive Landscape

Major players operating in the global urethral stricture treatment market include C. R. Bard, Inc., Amecath, Uromed, MedNova, Allium Medical, Surgimedik, Cook Medical Inc., Mednova, Taewoong Medical, Teleflex Incorporated, B. Braun Holding GmbH & Co. KG, Urotech, Coloplast Ltd, Boston Scientific Corporation, and Pnn Medical A/S. Key players are focusing on expanding their product portfolio, in order to retain dominant position in the market. For instance, Allium Medical, which manufactures and markets minimally invasive products, entered into the market with its product, Allium’s Ureteral Stents, which has some unique composition and better bio-compatibility.

Browse Complete Report For More Information @ http://bit.ly/2IOM4FA

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]